# Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00002592** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** c-myb antisense oligonucleotide G4460
- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** in vitro-treated bone marrow transplantation

## Key facts

- **NCT ID:** NCT00002592
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-06
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2015-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002592, "Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00002592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*